medical professional

CAF’s $300,000 Medical Research Funding Moves Field Forward

August 25, 2014 – New explorations in gene editing. Connections between thyroid hormones and hemoglobin. Efficiency and safety in gene therapy. Using a protein to control iron. These are the ideas behind the four exciting new studies being funded by the Cooley’s Anemia Foundation this year. These new fellowships join four renewed fellowships and a […]

Read more


Presentations from 2014 CAF Patient~Family Conference

August 20, 2014 – Below are links to the slides that were used in many of the presentations from this summer’s Patient~Family Conference. Please click through to view the slides. Presentations are listed alphabetically. The CHOP-HUP Transition Program – The Philadelphia Experience Fertility in Thalassemia Gene Therapy and Other Curative Approaches Genome Editing for Thalassemia The […]

Read more


TIF Schedules 4th Pan-European Conference

July 30, 2014 – TIF (Thalassaemia International Federation) has scheduled its 4th Pan-European Conference on Haemoglobinopathies and Rare Anaemias for November 7-9 in Athens, Greece. The Conference is held in collaboration with the Greek Thalassaemia Federation. Writing about the event on the Conference’s website (www.tif2014.org), TIF President Panos Englezos and Greek Thalassaemia Federation President Dr. […]

Read more




Register Now for 2014 CAF Patient-Family Conference!

February 27, 2014 – Registration is now open for CAF’s 2014 Patient~Family Conference! This amazing annual event will be held June 20-22 at the Intercontinental Chicago-O’Hare Hotel in Rosemont, Il. Entitled “Perspectives & Strategies for Thalassemia Care & Curative Options,” the Conference is a unique opportunity for any individual with thalssemia and their family members […]

Read more


Adherence Strategies: Q&A with Dr. Richard Ward

February 13, 2014 -The Cooley’s Anemia Foundation often gets questions and comments concerning strategies for remaining adherent to thalassemia treatments. We have asked Dr. Richard Ward of Toronto General Hospital to respond to some of these questions.  CAF thanks Dr. Ward for taking the time to share his knowledge and experience with us and with […]

Read more


CDC Announces Funding Opportunity in Thalassemia Pilot Interventions

The following is a notice that, RFA-DD-14-003, “Pilot Interventions to Promote the Health of People with Blood Disorders,” has been published with the correct dates on Grants.gov, December 23, 2013. → Deadline date is: March 06, 2014. To Access the Announcement & Application Package: 1. Go to: www.grants.gov 2. Select: “Applicants” from the top menu 3. Select: “Apply for Grants” 4. Select: […]

Read more


bluebird bio’s Northstar Study in Gene Transfer

bluebird bio, a Cambridge, MA- based biotechnology company, is sponsoring the Northstar Study, investigating gene transfer as a curative option for beta-thalassemia. More information about the study, including eligibility requirements, can be found at http:///www.northstarstudy.com. The Northstar Study is now enrolling adults who are transfusion dependent and diagnosed with a beta thalassemia major. The goal […]

Read more


bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia

December 2, 2013 – bluebird bio, Inc. today announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 HGB-205 study in France and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation. “We believe gene therapy represents a potentially new and exciting treatment […]

Read more


Secured By miniOrange